Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Dec. 6 '25)

Image
By G.M.

 


    Antiviral Res

  1. XIONG R, Wu Y, Wang Y, Qu Z, et al
    Rapid generation of a murine RSV infectious model by transducing a conditional knock-in mouse harboring human IGF1 receptor with adenoviral vector.
    Antiviral Res. 2025;244:106304.
    PubMed         Abstract available

  2. SUTTO-ORTIZ P, Selisko B, Ferron F, Sommadossi JP, et al
    Mapping the impact of 1'-, 2'- and 4'-nucleotide modifications on the Respiratory Syncytial Virus RNA-dependent RNA polymerase.
    Antiviral Res. 2025;244:106298.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  3. MOHAMMED A, Ibrahim NA, Basher NS
    Innovations and challenges in vaccine development: Lessons from the SARS-CoV-2 pandemic and prospects.
    Biochem Biophys Res Commun. 2025;792:152947.
    PubMed         Abstract available


    J Gen Virol

  4. METAXAKI M, Ram R, Perera M, Wills M, et al
    Robust antibody and T cell responses tracked longitudinally in patients with long COVID.
    J Gen Virol. 2025;106:002172.
    PubMed         Abstract available


    J Infect Dis

  5. SUMNER KM, Katz M, Hirsch A, Peretz A, et al
    Improved immune response against influenza A viruses with receipt of a recombinant influenza vaccine in healthcare personnel with prior low antibody response to egg-based influenza vaccines, Israel, 2019-20.
    J Infect Dis. 2025 Dec 3:jiaf605. doi: 10.1093.
    PubMed         Abstract available


    N Engl J Med

  6. GUAN L, Pattinson D, Eisfeld AJ, Wang T, et al
    Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk.
    N Engl J Med. 2025;393:2271-2273.
    PubMed        


    PLoS Med

  7. HEITKAMP P, Chijioke-Akaniro O, Pai M
    From dependence to self-reliance: The future of the global tuberculosis response.
    PLoS Med. 2025;22:e1004824.
    PubMed         Abstract available


    PLoS One

  8. SVENSSON AM, Bjornson M, Skold M, Kauczor HU, et al
    Pulmonary vascular and airway changes in previously hospitalised COVID-19 patients: Long-term functional respiratory imaging findings correlate with reduced DLCO.
    PLoS One. 2025;20:e0335075.
    PubMed         Abstract available

  9. DOI L, Morrison K, Anago EK, Hughes T, et al
    Evaluation of the delivery of the family nurse partnership programme in Scotland during the COVID-19 pandemic.
    PLoS One. 2025;20:e0337080.
    PubMed         Abstract available

  10. EL-AKKAD SE, Shao S, Tran KC, Naik H, et al
    Association between COVID-19 vaccination, SARS-CoV-2 variants, and post COVID-19 condition: A cross-sectional study.
    PLoS One. 2025;20:e0336929.
    PubMed         Abstract available

  11. RAHIMIPOUR ANARAKI N, Mukhopadhyay M, Patey C, Norman P, et al
    Factors Iinfluencing SurgeCon Implementation in Four Canadian Emergency Departments Guided by Consolidated Framework for Implementation Research.
    PLoS One. 2025;20:e0337389.
    PubMed         Abstract available

  12. SHEIKH F, Dolovich M, Schwartz L, Khan S, et al
    Evaluating N95 respirator designs: A mixed-methods pilot and feasibility study.
    PLoS One. 2025;20:e0328746.
    PubMed         Abstract available

  13. LEET DE, Jin J, Craik CS, Kattah MG, et al
    Post-vaccination SARS-CoV-2 neutralizing antibodies in pregnant women receiving biologics for inflammatory bowel disease.
    PLoS One. 2025;20:e0321242.
    PubMed         Abstract available

  14. SAMA SR, Gore R, Bauer AZ, Garber L, et al
    Autoimmune diseases as pre-existing conditions and sequelae of post COVID-19 condition in a Massachusetts community based observational study of COVID-19 patients.
    PLoS One. 2025;20:e0337848.
    PubMed         Abstract available

  15. HAMADOU M, Bakwo Bassogog CB, Obadias FV, Assaly AD, et al
    Moringa oleifera potential for the treatment and prevention of COVID-19 involving molecular interaction, antioxidant properties and kinetic mechanism.
    PLoS One. 2025;20:e0337904.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  16. JAMIESON KH, Gibson LA, Jamieson PE, Patterson S Jr, et al
    Using a mental model approach to undercut the effects of exposure to mRNA vaccination misconceptions: Two randomized trials.
    Proc Natl Acad Sci U S A. 2025;122:e2517067122.
    PubMed         Abstract available


    Vaccine

  17. GENSOROWSKY D, Surmann B, Meyer AC, Poshtiban A, et al
    Outpatient care intensity and influenza vaccination: evidence from Germany.
    Vaccine. 2025;70:128038.
    PubMed         Abstract available

  18. FILIPE JAN, Wong CKH, van Leeuwen E, Goodfellow L, et al
    A systematised review of seasonal influenza case-fatality risk.
    Vaccine. 2025;60 Suppl 2:128011.
    PubMed         Abstract available

  19. COOPER SC, Williams IV, Porter A, Presti C, et al
    'They're not going to tell you everything': A qualitative study with HPV vaccine hesitant parents and caregivers in the northeast and southeast U.S.
    Vaccine. 2025;68:127948.
    PubMed         Abstract available

  20. DEVSAM B, Bortolussi K, Tippins J, Vasiliadis S, et al
    The experience of seeking & granting special medical exemptions for mandated vaccines: A scoping review.
    Vaccine. 2025;68:127935.
    PubMed         Abstract available

  21. TALESHI J, Paramo MV, Watts A, Chilvers M, et al
    Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada.
    Vaccine. 2025;68:127936.
    PubMed         Abstract available

  22. GARVEY K, Salmon DA, Dudley MZ, Brewer J, et al
    Associations between trust in public health, vaccine confidence, and COVID-19 vaccination among American adults.
    Vaccine. 2025;68:127955.
    PubMed         Abstract available

  23. COUTO P, Campbell H, Li Y, Rondy M, et al
    Implications of respiratory syncytial virus seasonality for the timing of passive immunisation scenarios in Latin America and the caribbean - a cross-sectional modelling study.
    Vaccine. 2025;68:127934.
    PubMed         Abstract available

  24. BICEGO A, Wood JG, Newall AT, Hogan AB, et al
    Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies.
    Vaccine. 2025;68:127868.
    PubMed         Abstract available

  25. GROMER DJ, Kalash S, Tanios R, Rouphael N, et al
    The relationship between the immunogenicity and reactogenicity of vaccines: A narrative review.
    Vaccine. 2025;68:127892.
    PubMed         Abstract available

  26. REINHOLM A, Khan H, Laakso T, Maljanen S, et al
    Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1.
    Vaccine. 2025;68:127894.
    PubMed         Abstract available

  27. THAWEETHAI T, Gross RS, Pant DB, Rhee KE, et al
    Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection.
    Vaccine. 2025;68:127907.
    PubMed         Abstract available

  28. SAITO T, Couzinet A, Suzuki T, Shimomura M, et al
    Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
    Vaccine. 2025;68:127942.
    PubMed         Abstract available

  29. ZHANG Q, Lewis KB, Phillips JC, Ma H, et al
    Decisional needs of older adults considering COVID-19 booster vaccinations: A systematic review comparing China with other countries.
    Vaccine. 2025;68:127949.
    PubMed         Abstract available

  30. ZIDAN M, Trinh NTH, Desalegn A, Smith LH, et al
    BNT162b2 mRNA COVID-19 vaccine effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries.
    Vaccine. 2025;68:127908.
    PubMed         Abstract available

  31. O'BRIEN TL, Johnson DR
    U.S. state lawmaker support for COVID-19 vaccine policies during the pandemic.
    Vaccine. 2025;68:127930.
    PubMed         Abstract available


    Virology

  32. JEFFREE CE, Lu TB, Tan BH, Sugrue RJ, et al
    Analysis of the surface topology of respiratory syncytial virus particles that form on the surface of virus-infected cells.
    Virology. 2026;614:110732.
    PubMed         Abstract available

  33. GARRY RF
    SARS-CoV-2 Spike displays multiple adaptive changes in addition to the furin cleavage site.
    Virology. 2026;614:110720.
    PubMed         Abstract available

  34. POPOVIC ME, Stevanovic M, Tadic V
    COVID-19 ante portas: Empirical formula, growth reactions and thermodynamic properties of biosynthesis and antigen-receptor binding of the Omicron XFG variant of SARS-CoV-2.
    Virology. 2026;614:110742.
    PubMed         Abstract available

  35. RIVETTI AV JR, Reischak D, Carnegie L, Otaka JNP, et al
    Genomic diversity and reassortment of highly pathogenic avian influenza A/H5N1 virus (clade 2.3.4.4b) in Brazil: Evidence of multiple introductions and intra-epidemic reassortment in 2025.
    Virology. 2025;615:110751.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »